Fig. 6

SLC7A7 activation of Wnt/β-catenin signaling pathway promotes colon cancer progression through the EMT process and m7g modification promotes SLC7A7 mRNA stabilization. (A) Enrichment analysis results showed that SLC7A7 significantly enriched in EMT Apoptosis Hormone ER et al. (B) Activity of EMT pathway between high(n = 243) and low(n = 243) SLC7A7 expression groups in COAD. (C) The APC expression of si-SLC7A7 was analyzed by qRT-PCR and WB in HCT116 and SW480 cells. (D) The expression of E-cadherin, ZO-1 β-catenin in HCT116 and SW480 cells transfected with SLC7A7 siRNA was detected by Western blot. (E) The m7g-hub website predicts the SLC7A7 mRNA m7g modification site. (F) The m7g antibody specifically enriches SLC7A7 mRNA. (G) The efficiency of QKI siRNA was detected using qRT-PCR and WB in SW480 cells. (H) Analysis of SLC7A7 mRNA levels in down-regulated QKI SW480 cells incubated with actinomycin D for 0 h, 4 h, 8 h, 12 h, and 24 h by qRT-PCR. (I)The efficiency of OV METTL1 was detected using qRT-PCR, analysis of SLC7A7 mRNA levels in overexpression METTL1 SW480 cells incubated with actinomycin D for 0 h, 4 h, 12 h, and 20 h by qRT-PCR.analysis of SLC7A7 mRNA levels in OV-METTL1-mutant SW480 cells incubated with actinomycin D for 0 h, 4 h, 12 h, and 20 h by qRT-PCR.